Pancreatic cancer in the MENA region, a bibliometric review.
MENA region
bibliometrics
oncology
pancreatic cancer
research
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2022
2022
Historique:
received:
25
10
2021
entrez:
15
6
2022
pubmed:
16
6
2022
medline:
16
6
2022
Statut:
epublish
Résumé
Most Middle East and North Africa (MENA) countries record pancreatic cancer incidence rates that are above the world's average. Reducing this burden requires evidence-based policies. This bibliometric review aims to examine the status of pancreatic cancer research in the MENA world, while systematically categorising publications across cancer care pathways. We searched Scopus, Medline and PubMed for peer-reviewed publications related to both pancreatic cancer and MENA countries by using controlled vocabulary and keywords. The results were screened for duplicates and later included in the analysis based on preset eligibility criteria. A structured data extraction form was used to collect data related to each article, its methodology, its cancer care pathway, funding status and authorship. A total of 5,848 publications resulted from our search, from which 1,098 articles remained after applying the eligibility criteria. Trends show a steady increase in pancreatic cancer research by MENA. Case reports are the most common, whereas a lack in high-evidence clinical studies as well as public health and epidemiological research was evident. Most studies were not funded and had no female contributions. Funding, if present, came mostly from foreign states. There exists a much greater focus in research on diagnosis and treatment among other cancer care pathways. Most MENA-based studies did not involve collaborations with other countries. Country gross domestic product and population are both correlated to the research output. This bibliometric analysis identified significant gaps and limitations in pancreatic cancer research in MENA countries. Vital domains requiring research investment have also been highlighted as a first step towards evidence-based health policies.
Sections du résumé
Background
UNASSIGNED
Most Middle East and North Africa (MENA) countries record pancreatic cancer incidence rates that are above the world's average. Reducing this burden requires evidence-based policies. This bibliometric review aims to examine the status of pancreatic cancer research in the MENA world, while systematically categorising publications across cancer care pathways.
Methods
UNASSIGNED
We searched Scopus, Medline and PubMed for peer-reviewed publications related to both pancreatic cancer and MENA countries by using controlled vocabulary and keywords. The results were screened for duplicates and later included in the analysis based on preset eligibility criteria. A structured data extraction form was used to collect data related to each article, its methodology, its cancer care pathway, funding status and authorship.
Results
UNASSIGNED
A total of 5,848 publications resulted from our search, from which 1,098 articles remained after applying the eligibility criteria. Trends show a steady increase in pancreatic cancer research by MENA. Case reports are the most common, whereas a lack in high-evidence clinical studies as well as public health and epidemiological research was evident. Most studies were not funded and had no female contributions. Funding, if present, came mostly from foreign states. There exists a much greater focus in research on diagnosis and treatment among other cancer care pathways. Most MENA-based studies did not involve collaborations with other countries. Country gross domestic product and population are both correlated to the research output.
Conclusion
UNASSIGNED
This bibliometric analysis identified significant gaps and limitations in pancreatic cancer research in MENA countries. Vital domains requiring research investment have also been highlighted as a first step towards evidence-based health policies.
Identifiants
pubmed: 35702406
doi: 10.3332/ecancer.2022.1380
pii: can-16-1380
pmc: PMC9117003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1380Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Pharmacotherapy. 2006 Jun;26(6):759-67
pubmed: 16716129
Cancer. 2020 Jun 15;126(12):2859-2865
pubmed: 32212334
Handb Exp Pharmacol. 2020;257:383-398
pubmed: 31628602
J Glob Health. 2018 Dec;8(2):020411
pubmed: 30410737
J Family Community Med. 2015 Jan-Apr;22(1):25-30
pubmed: 25657608
Implement Sci. 2012 Jul 04;7:61
pubmed: 22762158
Lancet. 2011 Aug 13;378(9791):607-20
pubmed: 21620466
N Engl J Med. 2010 Apr 29;362(17):1605-17
pubmed: 20427809
East Mediterr Health J. 2012 Dec;18(12):1229-38
pubmed: 23301398
Int J Cardiol. 2015 Sep 15;195:155-62
pubmed: 26043150
World J Gastroenterol. 2016 Nov 28;22(44):9694-9705
pubmed: 27956793
Br J Cancer. 2011 Dec 6;105 Suppl 2:S77-81
pubmed: 22158327
Int J Cancer. 2005 Oct 10;116(6):963-71
pubmed: 15880414
Front Public Health. 2020 May 19;8:209
pubmed: 32574298
Epidemiol Rev. 2000;22(1):145-54
pubmed: 10939021
Clin Exp Gastroenterol. 2021 Feb 10;14:45-57
pubmed: 33603433
Lancet. 2020 Jun 27;395(10242):1968-1970
pubmed: 32563275
BMC Womens Health. 2015;15:25
pubmed: 25783656
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Cancer Lett. 2016 Oct 10;381(1):269-77
pubmed: 27461582
Oncologist. 2000;5(5):393-404
pubmed: 11040276
Ecancermedicalscience. 2020 Oct 29;14:1129
pubmed: 33209120
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Epidemiol. 1997 Dec;7(4):187-97
pubmed: 9465542
Lancet. 2014 Jan 25;383(9914):343-55
pubmed: 24452043